Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

41. New generation anticoagulants may be safer than warfarin for people with chronic kidney disease

New generation anticoagulants may be safer than warfarin for people with chronic kidney disease New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Discover Portal Discover Portal New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Published on 26 April 2016 doi: Newer generation anticoagulants appear to reduce the risk of bleeding compared with older anticoagulants like warfarin, when used to prevent clots (...) in people who also have mild to moderate chronic kidney disease. This group of drugs, called direct oral anticoagulants, have been well researched in healthy people with atrial fibrillation or at risk of thromboembolism but this was the first review to look at their safety, in terms of bleeding and risk of bleeding within the brain, in people with kidney disease. As a group, these newer drugs appear safer than older anticoagulants such as warfarin. Evidence from the trials comparing individual new

2019 NIHR Dissemination Centre

42. An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart

An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart Discover Portal Discover Portal An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart Published on 14 June 2016 doi: Bivalirudin is currently recommended as an alternative option to heparin to prevent (...) procedures were carried out in the UK. It involves inserting a small tube called a stent into the heart’s arteries, to hold them open. Anticoagulant treatment is needed at the same time to reduce the risk of clotting during and after the procedure. Heparin is the long established anticoagulant, but newer bivalirudin may now be used as an alternative. To date, different trials have produced contradictory evidence comparing the safety and effectiveness of the two anticoagulants when given to patients

2019 NIHR Dissemination Centre

43. Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation

Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Discover Portal Discover Portal Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Published on 6 February 2018 doi: In people with atrial fibrillation needing anticoagulant treatment, deaths were fewer (...) in those who had direct acting oral anticoagulants compared with warfarin. The picture is less clear for the risk of stroke and complications such as bleeding in the brain or gut. Apixaban had the best efficacy and safety profile and was cost-effective compared with warfarin. This study pooled the data in all trials reporting efficacy, safety and cost of anticoagulant prevention of stroke events in people with atrial fibrillation. Researchers used a technique called network meta-analysis to compare

2019 NIHR Dissemination Centre

44. Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation

Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Discover Portal Discover Portal Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Published on 18 July 2017 doi: General practice software that generated screen reminders for patients with atrial fibrillation did not increase the proportion taking oral anticoagulants (...) appropriately by six months. This NIHR-funded trial included GPs in 47 surgeries in England and found that at the start only 63% of eligible patients with atrial fibrillation were being prescribed anticoagulants. Six months later the rate had increased to 66% in intervention practices and 64% in those following usual practice, a non-significant difference between the groups. Use of the software was associated with increased diagnosis of transient ischemic attack, which could be due to improved detection

2019 NIHR Dissemination Centre

45. Extending anticoagulant treatment beyond three months reduces the risk of recurrent blood clots

Extending anticoagulant treatment beyond three months reduces the risk of recurrent blood clots Extending anticoagulant treatment beyond three months reduces the risk of recurrent blood clots Discover Portal Discover Portal Extending anticoagulant treatment beyond three months reduces the risk of recurrent blood clots Published on 1 March 2016 doi: Warfarin, newer direct oral anticoagulants and aspirin all significantly reduced the rate of recurrent clots in patients treated for more than (...) the standard three months. Aspirin was the least effective and the number of major bleeds and deaths was low in all three groups. This review pooling seven trials found that between six and 36 months 28 in every 1000 people taking warfarin, direct oral anticoagulants or aspirin after a first blood clot developed a second clot. This was significantly fewer than the 97 per 1000 people who developed a second clot while taking placebo. The cost-effectiveness of extending treatment was not assessed. People who

2019 NIHR Dissemination Centre

46. The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews

The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews anticoagulation medicines 18 March 2019 Links Download reports (pdf) Evidence Summary Evidence Report The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews. What do we want to know? Anticoagulation drugs are used to prevent and treat irregular heartbeat (atrial fibrillation, AF), and clotting of blood in veins (venous thromboembolism, VTE (...) ). Until recently, warfarin was the only available drug to manage or prevent these conditions. Recently, novel oral anticoagulants (NOACs) have become available for prescription. To bring together current understanding about these treatments, we sought to address broad research questions: What evidence syntheses have been conducted to address the efficacy and safety of UK-approved oral anticoagulant therapy with respect to warfarin, novel oral anticoagulants, genotyping (i.e. using genetic information

2019 EPPI Centre

47. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials Full Text available with Trip Pro

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta-analysis, we aimed to assess outcomes with reduced-dose NOACs when given as pre-specified in pivotal trials.Aggregated data abstracted from Phase III trials (...) , fatal bleeding, and death regardless of patient eligibility for NOAC dose reduction (interaction P > 0.05 for each).Patients eligible for reduced-dose NOACs were at elevated risk of thromboembolic and haemorrhagic complications when treated with anticoagulants. NOACs, when appropriately dose-adjusted, had an improved benefit-harm profile compared with warfarin. Our findings highlight the importance of prescribing reduced-dose NOACs for indicated patient populations.Published on behalf

2019 EvidenceUpdates

48. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) (Abstract)

Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) Guidelines recommend warfarin continuation rather than heparin bridging for pacemaker and defibrillator surgery, after the BRUISE CONTROL trial demonstrated an 80% reduction in device pocket haematoma with this approach. However, direct oral anticoagulants (DOACs) are now used to treat the majority of patients (...) -operation, interruption of anticoagulation, or prolonging hospital stay. In the continued arm, the median time between pre- and post-operative DOAC doses was 12 h; in the interrupted arm the median time was 72 h. Clinically significant haematoma occurred in of 7 of 328 (2.1%; 95% CI 0.9-4.3) patients in the continued DOAC arm and 7 of 334 (2.1%; 95% CI 0.9-4.3) patients in the interrupted DOAC arm (P = 0.97). Complications were uncommon, and included one stroke and one symptomatic pericardial effusion

2019 EvidenceUpdates

49. Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review

Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

50. Effect of novel oral anticoagulants in adult patients with or at risk for coronary artery disease or peripheral artery disease: a systematic review and meta-analysis of randomized trials

Effect of novel oral anticoagulants in adult patients with or at risk for coronary artery disease or peripheral artery disease: a systematic review and meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

51. Economic and clinical outcomes of oral anticoagulant management services: does pharmacist management differ from that of other health professionals? A systematic review and meta-analysis

Economic and clinical outcomes of oral anticoagulant management services: does pharmacist management differ from that of other health professionals? A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

52. Comparison of the association between antiplatelet drugs or anticoagulation agents with carotid intraplaque hemorrhage: a meta-analysis

Comparison of the association between antiplatelet drugs or anticoagulation agents with carotid intraplaque hemorrhage: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

53. Comparative effectiveness of oral anticoagulants in non-valvular atrial fibrillation in elderly patients

Comparative effectiveness of oral anticoagulants in non-valvular atrial fibrillation in elderly patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2019 PROSPERO

54. Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale (PFO): systematic review and meta-analysis of randomized controlled trials

Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale (PFO): systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

55. Prophylactic anticoagulation for patients with malignancy: a network meta-analysis of randomized controlled trials

Prophylactic anticoagulation for patients with malignancy: a network meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

56. The efficacy and safety of prothombin complex concentrate for the reversal of the effects of factor Xa inhibitor anticoagulants

The efficacy and safety of prothombin complex concentrate for the reversal of the effects of factor Xa inhibitor anticoagulants Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

57. What is the most clinically and cost effective combination of antiplatelet and anticoagulant therapies for people who have had an ACS and a separate indication for anticoagulation?

What is the most clinically and cost effective combination of antiplatelet and anticoagulant therapies for people who have had an ACS and a separate indication for anticoagulation? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

58. Anticoagulation - oral

Anticoagulation - oral Anticoagulation - oral - NICE CKS Share Anticoagulation - oral: Summary There are five oral anticoagulants licensed for use in the UK: warfarin, apixaban, dabigatran, edoxaban and rivaroxaban. Apixaban, dabigatran, edoxaban and rivaroxaban are newer anticoagulants which may be prescribed instead of warfarin for people with non-valvular atrial fibrillation (NVAF): Apixaban, dabigatran, edoxaban and rivaroxaban have been approved by the National Institute for Health (...) , regular follow up and monitoring is still required to: Assess compliance. Enquire about the presence of any adverse effect (e.g. bleeding). Assess for the presence of thromboembolic events (e.g. symptoms of stroke, or breathlessness which may suggest a pulmonary embolism). The most common adverse effect of anticoagulants is bleeding; however, while there is an antidote for warfarin, of the new anticoagulants, there is currently only an antidote for dabigatran. Management of a bleeding complication

2019 NICE Clinical Knowledge Summaries

59. Direct oral anticoagulation versus warfarin for postoperative atrial fibrillation following cardiac surgery: a systematic review and meta-analysis

Direct oral anticoagulation versus warfarin for postoperative atrial fibrillation following cardiac surgery: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

60. Direct effectiveness and safety comparison of direct-acting oral anticoagulants (DOACs): a systematic review and meta-analysis of real world studies

Direct effectiveness and safety comparison of direct-acting oral anticoagulants (DOACs): a systematic review and meta-analysis of real world studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO